The extracellular matrix in multiple sclerosis: An update

Brazilian Journal of Medical and Biological Research

Volumn 34, Issue 5, 2001, Pages 603-609

  Sobel, R A ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Axon regeneration; Central nervous system; Extracellular matrix; Multiple sclerosis; Proteoglycans; Versican

Indexed keywords

PROTEOGLYCAN; SCLEROPROTEIN;

BRAIN; CELL ADHESION; CELL COMMUNICATION; CELLULAR IMMUNITY; ENDOTHELIUM; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE FIBER; NERVE REGENERATION; PATHOLOGY; PHYSIOLOGY; REVIEW;

AXONS; BRAIN; CELL ADHESION; CELL COMMUNICATION; ENDOTHELIUM; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE REGENERATION; PROTEOGLYCANS;

EID: 0035344676     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2001000500007     Document Type: Article

References (44)

1. Sobel RA (1998). The extracellular matrix in multiple sclerosis lesions. Journal of Neuropathology and Experimental Neurology, 57: 205-217.
2. Lucchinetti C, Brück W, Parisi J. Scheithauer B, Rodriguez M & Lassmann H (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of Neurology, 47: 707-717.
3. Archelos JJ, Storch MK & Hartung H-P (2000). The role of B cells and autoantibodies in multiple sclerosis. Annals of Neurology, 47: 694-706.
4. Smith-Norowitz T, Sobel RA & Mokhtarian FM (2000). B cells and antibodies in the pathogenesis of myelin injury in Semliki Forest virus encephalomyelitis. Cellular Immunology, 200: 27-35.
5. Salcedo R & Patarroyo M (1995). Constitutive αv ß3 integrin-mediated adhesion of human lymphoid B cells to vitronectin substrate. Cellular Immunology, 160: 165-172.
6. Shibayama H, Tagawa S, Hattori H, Inoue R, Katagiri S & Kitani T (1995). Laminin and fibronectin promote the chemotaxis of human malignant plasma cell lines. Blood, 86: 719-725.
7. Rafi A, Nagarkatti M & Nagarkatti PS (1997). Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood, 89: 2901-2908.
8. Briani C, Santoro M & Latov N (2000) Antibodies to chondroitin sulfates A, B, and C: clinico-pathological correlates in neurological diseases. Journal of Neuroimmunology, 108: 216-220.
9. Savettieri G, Di Liegro I, Catania C, Licata L, Pitarresi GL, D'Agostino S, Schiera G, De Caro V, Giandella G, Giannola LI & Cestelli A (2000). Neurons and ECM regulate occludin localization in brain endothelial cells. NeuroReport, 11: 1081-1084.
10. Sobel RA, Hinojoza JR, Maeda A & Chen M (1998). Endothelial cell integrin laminin receptor expression in multiple sclerosis lesions. American Journal of Pathology, 153: 405-415.
11. Cuzner ML & Opdenakker G (1999). Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. Journal of Neuroimmunology, 94: 1-14.
12. Cross AK & Woodroofe MN (1999). Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia, 28: 183-189.
13. Yong VW, Krekoski CA, Forsyth PA, Bell R & Edwards DR (1998). Matrix metalloproteinases and diseases of the CNS. Trends in Neurosciences, 21: 75-80.
14. Lukes A, Mun-Bryce S, Lukes M & Rosenberg GA (1999). Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Molecular Neurobiology, 19: 267-284.
15. Valenzuela MA, Cartier L, Collados L, Kettlun AM, Araya F, Concha C, Flores L, Wolf ME & Mosnaim AD (1998). Gelatnase activity of matrix metalloproteinases in the cerebrospinal fluid of various patient populations. Research Communications in Molecular Pathology and Pharmacology, 104: 42-52.
16. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G & Miller K (1999). Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology, 53: 1397-1401.
17. Sellebjerg F, Madsen HO, Jensen CV, Jensen J & Garred P (2000). CCR5 δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. Journal of Neuroimmunology, 102: 98-106.
18. Kieseier BC, Seifert T, Giovannoni G & Hartung HP (1999). Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology, 53: 20-25.
19. Wolswijk G (2000). Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain, 123: 105-115.
20. Keirstead HS & Blakemore WF (1999). The role of oligodendrocytes and Oligodendrocyte progenitors in CNS remyelination. Advances in Experimental Medicine and Biology, 468: 183-197.
21. Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z & Yong VW (1999). Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. Journal of Neuroscience, 19: 8464-8475
22. Milner R (1997). Understanding the molecular basis of cell migration: implications for clinical therapy in multiple sclerosis. Clinical Science, 92: 113-122.
23. Del Bigio MR, Tchélingérian J-L & Jacque CM (1999). Expression of extracellular matrix degrading enzymes during migration of xenografted brain cells. Neuropathology and Applied Neurobiology, 25: 53-61.
24. Kornek B & Lassmann H (1999). Axonal pathology in multiple sclerosis. A historical note. Brain Pathology, 9: 651-655.
25. Ferguson B, Matyszak MK, Esiri MM & Perry VH (1997). Axonal damage in acute multiple sclerosis lesions. Brain, 120: 393-399
26. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S & Bö L (1998). Axonal transection in the lesions of multiple sclerosis. New England Journal of Medicine, 338: 278-285.
27. Ganter P, Prince C & Esiri MM (1999). Spinal cord axonal loss in multiple scerosis: a post-mortem study. Neuropathology and Applied Neurobiology, 25: 459-467.
28. Evangelou N, Esiri MM, Smith S, Palace J & Matthews PM (2000). Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Annals of Neurology, 47: 391-395.
29. Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer III FE & Brownscheidle CM (1999). A longitudinal study of brain atrophy in relapsing multiple sclerosis The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology, 53: 139-148.
30. Tortorella C, Viti B, Bozzali M, Sormani MP, Rizzo G, Gilardi MF, Comi G & Filippi M (1999). A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology, 54: 186-193.
31. 1H Magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. Journal of Neurology, 246: 1023-1026.
32. Lee MA, Blamire AM, Pendlebury S, Ho K-H, Mills KR, Styles P, Palace J & Matthews PM (2000). Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Archives of Neurology, 57: 65-70.
33. Gutowski NJ, Newcombe J & Cuzner ML (1999). Tenascin-R and C in multiple sclerosis lesions: relevance to extracellular matrix remodeling. Neuropathology and Applied Neurobiology, 25: 207-214.
34. Trapp BD, Ransohoff R & Rudick R (1999). Axonal pathology in multiple sclerosis: relationship to neurologic disability. Current Opinion in Neurology, 12: 295-302.
35. Pires-Neto MA, Braga-de-Souza S & Lent R (1999). Extracellular matrix molecules play diverse roles in the growth and guidance of central nervous system axons. Brazilian Journal of Medical and Biological Research, 32: 633-538.
36. Yamaguchi Y (2000). Chondroitin sulfate proteoglycans in the nervous system. In: Iozzo RV (Editor), Proteoglycans - Structure. Biology, and Molecular Interactions. Marcel Dekker, New York.
37. Jander S, Schroeter M, Fischer J & Stoll G (2000). Differential regulation of microglial keratan sulfate immunoreactivity by proinflammatory cytokines and colony-stimulating factors. Glia, 30: 401-410.
38. Bovolenta P & Fernaud-Espinosa I (2000). Nervous system proteoglycans as modulators of neurite outgrowth. Progress in Neurobiology, 61: 113-132.
39. Zuo J, Neubauer D, Dyess K, Ferguson TA & Muir D (1998). Degradation of chondroitin sulfate proteoglycan enhances the neurite-promoting potential of spinal cord tissue Experimental Neurology, 154: 654-662.
40. Stichel CC, Niermann H, D'Urso D, Lausberg F, Hermanns S & Muller HW (1999). Basal membrane-depleted scar in lesioned CNS: characteristics and relationships with regenerating axons. Neuroscience, 93: 321-333.
41. McKeon RJ, Jurynec MJ & Buck CR (1999). The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar. Journal of Neuroscience, 19: 10778-10788.
42. Asher RA, Morgenstern DA, Fidler PS, Adcock KH, Oohira A, Braistead JE, Levine JM, Margolis RU, Rogers JH & Fawcett JW (2000). Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. Journal of Neuroscience, 20: 2427-2438.
43. Schmalfeldt M, Bandtlow CE, Dours-Zimmermann MT, Winterhalter KH & Zimmermann DR (2000). Brain derived versican V2 is a potent inhibitor of axonal growth. Journal of Cell Science, 113: 807-816.
44. Niederost BP, Zimmermann DR, Schwab ME & Bandtlow CE (1999). Bovine CNS myelin contains neurite growth-inhibitory activity associated with chondroitin sulfate proteoglycans. Journal of Neuroscience, 19: 8979-8989.